As of 2024, Akumin has expanded from external beam radiation therapy to include systemic radiation therapy using radiopharmaceuticals. These treatments deliver radiation directly to cancer cells while minimizing exposure to surrounding healthy tissue.
Radiopharma Treatments We Offer
Lutathera®
- FDA-approved for grade 1 neuroendocrine tumors not well controlled on lanreotide alone
- Approved as first-line therapy for grade 2–3 neuroendocrine tumors
Pluvicto®
- FDA-approved for second-line therapy after failing one ARPI
- Found to be more effective with fewer side effects compared to chemotherapy
- Delivered as a 30-minute infusion every six weeks for six sessions
- Our team monitors blood counts, kidney function, and manages side effects throughout treatment
Xofigo®
- FDA-approved for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no known visceral metastases
- Clinical studies showed an overall survival benefit (OS extended by 3.6 months in exploratory analysis)
- Administered as a 1-minute injection every four weeks for six sessions
Why Choose Akumin for Radiopharma?
- Comprehensive expertise in both external beam radiation and systemic radiopharmaceutical therapy
- Patient-centered care with close monitoring of safety and side effects
- Akumin-managed Personalized Radiation Oncology is designated as a Radiopharmaceutical Therapy Center of Excellence by the Society of Nuclear Medicine & Molecular Imaging
Interested in how Akumin can help establish or grow a Radiopharma group?
Contact our expert, David Chamberlain – david.chamberlain@akumin.com